Adderall XR Adds 13-17 Year-Old Age Group
This article was originally published in The Pink Sheet Daily
FDA clears extended-release amphetamine for treatment of attention deficit/hyperactivity disorder in adolescents ages 13-17. Expanded indication fills gap between previous approved populations: 6-12 year-olds and adults ages 18 and older.
You may also be interested in...
Company plans a "Dear Doctor" letter informing U.S. physicians of Health Canada's decision. FDA says it "has not decided to take any further regulatory action at this time"; sudden death warnings were added to Adderall XR's labeling in August.
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products